Global MDD Prevalence
18 % increase from 2005 to 20151
No. 1
burdensome illness -6%
(measured in DALY)
~$328B
US Economic Burden of MDD
(direct & indirect sosts) 2
Clear Need for New Therapeutics
33%
Treatment Resistant Depression of Patients with MDD respond inadequately to treatment3.
~38%
Side Effects
~38% of MDD patients experience one or more side effects on SSRI use
Upto 12 Weeks
Delayed Onset of Action
12 weeks before efficacy of SSRIs manifests in MDD
Multiple Weeks
Trial and Error
Multiple weeks before right drug and dosage for patient can be decided
Esketa
- mine
FDA Approvals
Esketamine-Latest Approval has-low Efficacy and very high cost and high Abuse Potential
MDD patients that do not respond to 2 lines of treatment, are classified to have Treatment Resistant Depression (TRD).
1. WHO 2020, 2. The Analysis Group 2021
Headache Disorders - Migraine Headache and Cluster Headaches
Market for Headache Disorders
~1200M
Global Migriaine Prevalence
(15 % globally)
No. 3
Among top 3 most disabling
diseases
~$17.5B
$11.5 B market by 2027
Clear Need for New Therapeutics
Long Term success of Migraine Therapeutics precluded due to -
Limited Efficacy
Limited Efficacy 30 to 35 percent do not respond to new CGRP agonists.
~38%
Side Effects
~38% of MDD patients experience one or more side effects on SSRI use.